MDNA Key Statistics, Chart & Performance
The current stock price of MDNA is 0.157 USD. In the past month the price decreased by -43.73%. In the past year, price decreased by -75.7%.
MDNA Latest News, Press Relases and Analysis
MDNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About MDNA
Company Profile
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Company Info
MEDICENNA THERAPEUTICS CORP
2 Bloor St W 7th Floor
TORONTO ONTARIO M4S 3E2 CA
CEO: Fahar Merchant
Employees: 18
Phone: 14166485555.0
MEDICENNA THERAPEUTICS CORP / MDNA FAQ
Can you describe the business of MEDICENNA THERAPEUTICS CORP?
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
What is the current price of MDNA stock?
The current stock price of MDNA is 0.157 USD. The price decreased by -13.16% in the last trading session.
Does MDNA stock pay dividends?
MDNA does not pay a dividend.
How is the ChartMill rating for MEDICENNA THERAPEUTICS CORP?
MDNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is MEDICENNA THERAPEUTICS CORP worth?
MEDICENNA THERAPEUTICS CORP (MDNA) has a market capitalization of 10.93M USD. This makes MDNA a Nano Cap stock.
What is the ownership structure of MEDICENNA THERAPEUTICS CORP (MDNA)?
You can find the ownership structure of MEDICENNA THERAPEUTICS CORP (MDNA) on the Ownership tab.
MDNA Technical Analysis
MDNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDNA. No worries on liquidiy or solvency for MDNA as it has an excellent financial health rating, but there are worries on the profitability.
MDNA Financial Highlights
Over the last trailing twelve months MDNA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 56.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.75% | ||
| ROE | -32.55% | ||
| Debt/Equity | 0 |
MDNA Forecast & Estimates
11 analysts have analysed MDNA and the average price target is 2.88 USD. This implies a price increase of 1735.48% is expected in the next year compared to the current price of 0.157.